MX2015015036A - Metodos para mejorar los perfiles de lipidos utilizando atrasentan. - Google Patents

Metodos para mejorar los perfiles de lipidos utilizando atrasentan.

Info

Publication number
MX2015015036A
MX2015015036A MX2015015036A MX2015015036A MX2015015036A MX 2015015036 A MX2015015036 A MX 2015015036A MX 2015015036 A MX2015015036 A MX 2015015036A MX 2015015036 A MX2015015036 A MX 2015015036A MX 2015015036 A MX2015015036 A MX 2015015036A
Authority
MX
Mexico
Prior art keywords
methods
atrasentan
cholesterol
subject
lipid profiles
Prior art date
Application number
MX2015015036A
Other languages
English (en)
Inventor
Blas Coll Crespo
Dennis Andress
Peter J Brennan
James C Stolzenbach
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2015015036A publication Critical patent/MX2015015036A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se dirige a métodos para reducir un riesgo cardiovascular en un sujeto humano al administrar atrasentan, o una sal farmacéuticamente aceptable del mismo, en una cantidad suficiente para llevar a cabo una reducción de aproximadamente 5% o más en uno o ambos de (a) colesterol total en suero, con relación al colesterol total en suero a valores iniciales del sujeto, y (b) colesterol de LDL en suero, con relación al colesterol de LDL en suero a valores iniciales del sujeto.
MX2015015036A 2013-04-30 2014-04-30 Metodos para mejorar los perfiles de lipidos utilizando atrasentan. MX2015015036A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361817645P 2013-04-30 2013-04-30
US201361824199P 2013-05-16 2013-05-16
PCT/US2014/036152 WO2014179453A1 (en) 2013-04-30 2014-04-30 Methods for improving lipid profiles using atrasentan

Publications (1)

Publication Number Publication Date
MX2015015036A true MX2015015036A (es) 2016-02-09

Family

ID=50928265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015036A MX2015015036A (es) 2013-04-30 2014-04-30 Metodos para mejorar los perfiles de lipidos utilizando atrasentan.

Country Status (13)

Country Link
US (1) US9855245B2 (es)
EP (1) EP2991680A1 (es)
JP (1) JP2016521279A (es)
KR (1) KR20160003128A (es)
CN (1) CN105246512A (es)
AU (1) AU2014259961A1 (es)
BR (1) BR112015027631A2 (es)
CA (1) CA2909871A1 (es)
HK (1) HK1221916A1 (es)
MX (1) MX2015015036A (es)
RU (1) RU2015151175A (es)
SG (1) SG11201508960SA (es)
WO (1) WO2014179453A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2591188C2 (ru) 2010-11-08 2016-07-10 Альбирео Аб Ингибиторы ibat для лечения заболеваний печени
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
BR112022012075A2 (pt) 2019-12-17 2022-08-30 Chinook Therapeutics Inc Métodos para tratar nefropatia por iga com atrasentan
AU2021252995A1 (en) * 2020-04-10 2022-10-06 Abbvie Inc. Methods of treating diabetic kidney disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (es) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5544163A (en) 1994-03-08 1996-08-06 Excel, Inc. Expandable telecommunications system
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
US20060189675A1 (en) 2004-09-17 2006-08-24 Steve King Crystalline form of a drug
WO2006034085A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form of atrasentan hydrochloride
CA2578824A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 2 of atrasentan hydrochloride
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
US20080132710A1 (en) 2006-12-04 2008-06-05 Abbott Laboratories Atrasentan hydrochloride crystalline form 2
CA2904447C (en) 2007-08-22 2017-01-03 Abbvie Deutschland Gmbh & Co Kg Therapy for complications of diabetes
CN101822837A (zh) * 2010-02-02 2010-09-08 王丽燕 包含艾力沙坦酯盐的药物组合物
US20160015701A1 (en) 2013-03-08 2016-01-21 Abbive Inc. Methods of Treating Acute Kidney Injury

Also Published As

Publication number Publication date
HK1221916A1 (zh) 2017-06-16
US20160074363A1 (en) 2016-03-17
BR112015027631A2 (pt) 2017-08-22
JP2016521279A (ja) 2016-07-21
KR20160003128A (ko) 2016-01-08
CA2909871A1 (en) 2014-11-06
US9855245B2 (en) 2018-01-02
AU2014259961A1 (en) 2015-11-05
CN105246512A (zh) 2016-01-13
EP2991680A1 (en) 2016-03-09
WO2014179453A1 (en) 2014-11-06
RU2015151175A (ru) 2017-06-07
SG11201508960SA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
MX2015015036A (es) Metodos para mejorar los perfiles de lipidos utilizando atrasentan.
WO2014004993A3 (en) Methods of reducing ldl-p
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
IN2015DN03219A (es)
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
BR112015020209A2 (pt) uso de linagliptina em terapia antidiabética de proteção cardíaca e renal
AU2011328009A8 (en) Compounds and methods for treating pain
IN2014DN10386A (es)
AU2012229123A8 (en) Methods of treating breast cancer with anthracycline therapy
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
IN2014MN01892A (es)
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX364220B (es) Metodos de tratamientos de fibrosis.
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
NZ628433A (en) Chitosan-derived compositions
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
NZ616048A (en) Administration of iloprost as aerosol bolus
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
PH12016500142A1 (en) Vesicles
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2015005111A (es) Composicion a base de hierbas para la prevencion y tratamieto de tnf-a una enfermedad mediada.
MX2015006370A (es) Suplementos herbales y metodos para utilizar los mismos.
EP2563350A4 (en) THERAPEUTIC REGIME AND METHOD FOR THE TREATMENT OR IMPROVEMENT OF VIEW DISORDERS ASSOCIATED WITH ENDOGENOUS RETINOID DEFICIENCY
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.